VNDA: Summary for Vanda Pharmaceuticals Inc. - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, February 10, 2010, 2:02am EST - Canadian Markets open in 7 hours and 28 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Vanda Pharmaceuticals, Inc. (VNDA)

On Feb 9: 10.60 USD

0.40 (3.92%)

MORE ON VNDA

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Vanda Pharmaceuticals Inc. (NGM:VNDA) Delayed quote data

After Hours: 10.20

0.40 (3.77%) as of 5:00pm EST on 02/09/10

Last Trade:	10.60 USD
Trade Time:	Feb 9
Change:	0.40 (3.92%)
Prev Close:	10.20
Open:	10.34
Bid:	N/A
Ask:	10.89 x 2000
1y Target Est:	19.67

Day's Range:	10.24 - 10.66
52wk Range:	0.60 - 16.65
Volume:	269,352
Avg Vol (3m):	461,687
Market Cap:	288.33M
P/E (ttm):	N/A
EPS (ttm):	-2.58
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y

Add VNDA to Portfolio

Download Data

HEADLINES

•	Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2009 Financial Results on February 16, 2010
	PRNewswire (Tue 2:09pm)

•	These Stocks Can Easily Double Your Money
	at Motley Fool (Wed, Jan 20)

•	Competitive Schizophrenia Market
	Zacks.com (Tue, Jan 12)

•	VANDA PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex
	EDGAR Online (Mon, Jan 11)

•	Drug News: Impotence, Arthritis and Schizophrenia
	at The Wall Street Journal Online (Mon, Jan 11)

•	Sales start for Vanda Pharmaceuticals schizophrenia treatment
	at bizjournals.com (Mon, Jan 11)

•	Fanapt(TM) Launches in the U.S.
	PRNewswire (Mon, Jan 11)

•	Biotech's Movers and Shakers 2009: BioBuzz
	at TheStreet.com (Mon, Jan 4)

•	Biotech's Movers & Shakers 2009: BioBuzz
	at TheStreet.com (Mon, Jan 4)

•	Biotech's 2009 Movers & Shakers: BioBuzz
	at TheStreet.com (Mon, Jan 4)

•	Nasdaq 2009 Winners & Losers
	at TheStreet.com (Thu, Dec 31)

•	Millennial Stocks - Up By Over 1,000% In 2009
	at Investopedia (Thu, Dec 31)

More Headlines for VNDA...

ANALYST

EPS Est (next year) (Dec-07) :	N/A
EPS Est (in 2 years) (Dec-08) :	N/A
Avg Rec (current)*:	1.9
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Vanda Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of clinical-stage drug candidates for various central nervous system disorders.

Full Company Profile

Add to Portfolio

Email to a Friend

•